PSA Test in SA: What Your Result Actually Means

A small blood test. A number on a piece of paper. And then — often — silence. Thousands of South African men receive PSA results every year without anyone explaining what the figure actually means. That gap isn’t just frustrating; in a country where prostate cancer is the most common cancer in men and the healthcare counselling divide between public and private is structural and permanent, it can cost lives.

This article does not tell you whether to get tested. It tells you how to read what you’ve got.

First, the scare you’ve probably heard about

Before unpacking the science, one misconception needs naming directly: the 2012 United States Preventive Services Task Force recommendation against routine PSA screening. That recommendation was widely reported in SA media and led many men — and some clinicians — to conclude that the PSA test was useless. It was not a fair summary.

The USPSTF was responding to real evidence of over-treatment in the US system, where borderline results were leading to aggressive surgery and radiation with serious side effects. By 2018, the same task force reversed course for men aged 55–69, recommending shared decision-making rather than blanket avoidance. The lesson is not that the test is bad; it is that the test result requires interpretation. That distinction matters enormously in SA, where prostate cancer is diagnosed later and at more aggressive stages than in high-income countries, partly because of delayed presentation and limited specialist access.

What the PSA test actually measures

PSA stands for prostate-specific antigen — a protein produced by both normal and abnormal prostate tissue. The test measures how much of this protein is circulating in your blood, reported in nanograms per millilitre (ng/mL).

The traditional threshold taught in medical schools is 4.0 ng/mL. Above that, the thinking went, investigate further. Below it, you’re probably fine. Reality is more complicated.

• A man with a PSA of 3.5 ng/mL can have aggressive prostate cancer.
• A man with a PSA of 6.0 ng/mL may have benign prostatic hyperplasia (BPH), a non-cancerous enlargement that becomes extremely common after 50.
• Infection (prostatitis), vigorous cycling, and even ejaculation within 48 hours of the test can temporarily elevate results.

What clinicians look for is not just a single number, but the trend over time (PSA velocity), how the level relates to the size of the prostate (PSA density), and the ratio of free to total PSA. A single isolated reading, without context, is close to meaningless as a verdict.

Why SA men face a different risk calculation

South African men carry a comorbidity burden that changes the clinical picture in ways that are not always communicated at the point of testing.

Hypertension affects an estimated 46% of South African adults according to the South African Medical Research Council (SAMRC). Some antihypertensive medications — particularly thiazide diuretics — may mildly influence inflammatory markers, and hypertension itself is associated with higher-grade prostate disease in several international studies. No dedicated SA dataset exists for this specific interaction, but the SAMRC’s non-communicable disease burden data makes this relevant for the majority of middle-aged men presenting for screening.

Type 2 diabetes affects roughly 4.2 million South Africans (Diabetes SA, 2023 estimate). Insulin resistance and elevated IGF-1 levels associated with poorly controlled diabetes are linked to faster prostate cell proliferation. Paradoxically, metformin — the most widely used first-line diabetic medication in the public sector — appears in multiple studies to have a modest protective effect on prostate cancer progression, though it is not a substitute for screening.

HIV is the context most specific to SA. The country has approximately 7.8 million people living with HIV (NICD, 2024). Men on antiretroviral therapy (ART) are living longer, which means their lifetime prostate cancer risk now registers in a way it previously did not. Immune activation associated with HIV, even when virologically suppressed, may influence PSA values. A 2021 review in the South African Medical Journal flagged that PSA interpretation in HIV-positive men requires additional caution because chronic immune stimulation can raise baseline PSA without indicating malignancy. If you are HIV-positive and receive a borderline PSA result, make sure your clinician knows your ART history and your most recent CD4 and viral load.

What your specific number might mean

Rather than a strict normal/abnormal split, most SA urologists now use age-adjusted reference ranges and risk stratification:

| Age group | Lower-risk PSA range |

| Under 50 | Below 2.5 ng/mL |

| 50–59 | Below 3.5 ng/mL |

| 60–69 | Below 4.5 ng/mL |

| 70 and over | Below 6.5 ng/mL |

These are discussion thresholds, not cut-offs. A result above the range for your age group means: have a conversation, not you have cancer.

If your PSA is elevated, the next typical step in both public and private settings is a repeat test (to exclude transient causes), followed by a digital rectal examination (DRE), and potentially an MRI or biopsy depending on the clinical picture. The SAMRC and the Cancer Association of South Africa (CANSA) both recommend that Black African men — who are at higher risk and tend to present with more aggressive disease — consider starting the screening conversation with their doctor from age 40 rather than the conventional 50.

Getting answers in the public and private systems

Public sector pathway: Your first point of contact is your nearest clinic or community health centre (CHC). A PSA test can be requested by a general nurse or doctor at primary care level and processed through the National Health Laboratory Service (NHLS). If your result warrants follow-up, you will be referred to a district or regional hospital’s outpatient urology or general surgery service. Waiting times for specialist consultation at district hospitals vary significantly — in some provinces, the wait exceeds three months. If you receive an elevated result and are in the public system, ask the clinic to note “query malignancy” on your referral letter; this can expedite triage.

Private sector costs: A PSA blood test at a private pathology lab (PathCare, Lancet, Ampath) typically costs R180–R350 without a medical aid. A GP consultation to discuss the result adds R400–R900 depending on billing level. A urology specialist consultation ranges from R900–R1,800 for the first appointment. An MRI of the prostate (multiparametric MRI, the current gold-standard pre-biopsy imaging) costs R6,000–R12,000 privately.

Medical aid coverage: Prostate cancer investigation falls under Prescribed Minimum Benefits (PMBs) once there is a diagnosis of prostate cancer. Screening and the investigative steps leading to a diagnosis are generally not automatically covered as PMBs — meaning your plan’s out-of-hospital benefit or day-to-day cover pays first. Check with your scheme before booking an MRI. Some open medical schemes cover PSA screening as a preventive benefit for men over 45; ask your scheme directly.

Practical barriers and workarounds: Load-shedding affects NHLS processing turnaround times at some facilities — results that should take 48 hours can take up to a week during extended outages. If you are in a rural area, the CANSA network has mobile health units that conduct PSA screening during awareness campaigns (typically August–September). Check cansa.org.za for dates near you.

How to have a useful conversation with your doctor

Go in with three questions:

1. What is my PSA trend? One reading tells you little. Ask for the previous result or request that this one be used as a baseline.
2. What other factors apply to me? Remind your doctor of any prostate symptoms (difficulty urinating, weak stream), your family history, and your HIV or diabetes status if relevant.
3. What would change the plan? Ask explicitly what the next step is if the result rises by 1.0 ng/mL per year, or if a repeat test in three months still shows the same figure. Get it in writing if possible.

When to see a doctor promptly

Book an appointment — don’t wait for your next routine visit — if you have:

– A PSA result above 10 ng/mL on a first test

– Bone pain in your lower back, hips, or pelvis alongside an elevated PSA

– Blood in your urine or semen

– Difficulty urinating that has worsened rapidly over weeks

– A family history of prostate cancer in a first-degree relative under 65

>

In all of these situations, ask specifically for a urology referral rather than a repeat PSA alone.

Bottom line

• Ask for context, not just a number — PSA velocity and age-adjusted ranges matter more than a single reading against a fixed threshold.
• Disclose your full health picture — HIV status, ART regimen, diabetes control, and antihypertensive medication all influence how your result should be interpreted.
• Black African men should start the conversation at 40, not 50, given higher-risk and later-stage diagnosis patterns in SA.
• Follow the public pathway actively — request a “query malignancy” referral note if your result is elevated; it moves you through the system faster.
• Medical aid won’t automatically cover the workup — confirm your benefits before booking imaging.